

Earnings Highlights

\$27.7B

Revenue
+53% Op Growth¹

\$1.73

Rep. Dil. EPS
+77% Growth

\$2.04

Adj. Dil. EPS²
+100% Op Growth

\$2.8B

Rep. R&D Expenses
+27% Op Growth

\$2.8B

Adj. R&D Expenses²
+27% Op Growth

FY 2022 Guidance³

Revenue
\$98B–\$102B

Adj. Dil. EPS² \$6.30–\$6.45

\$6.5B

Returned to Shareholders
Year-To-Date

\$4.5B Cash Dividends
\$2.0B Share Repurchases

"We made significant progress this quarter on our strategies to bring value to our patients and shareholders, while also making commitments to prioritize the broader needs of the world, including those of the environment and our most vulnerable populations. Even while launching these initiatives to support a healthier, more equitable world, we remain equally committed to strong financial execution on behalf of our shareholders."

Albert Bourla
Chairman and Chief Executive Officer



Key Growth Drivers⁴

Pfizer-BioNTech COVID-19 vaccine

\$8,848M Revenue
+20% Op Growth

PAXLOVIDTM COVID-19 Oral Treatment

\$8,115M Revenue

Eliquis[®]
(apixaban) tablets

\$1,745M Revenue
+23% Op Growth

Pprevnar Family
Pneumococcal Conjugate Vaccine

\$1,429M Revenue⁵
+18% Op Growth
+41% U.S. Growth

Vyndamax[®]
(tafamidis)

\$552M Revenue⁶
+16% Op Growth
+32% U.S. Growth

Pipeline Spotlights

Pfizer-BioNTech COVID-19 vaccine

Expanded emergency use as primary series for children 6 months-4 years and booster dose in children 5-11 years of age

Candidate
Pfizer-BioNTech Omicron-Adapted COVID-19 vaccine

Announced positive Phase 2/3 immunogenicity data of monovalent and bivalent Omicron-adapted COVID-19 vaccine candidates

Candidate
Etrasimod

Presented positive Phase 3 results in treating moderately to severely active ulcerative colitis

Candidate
Ervogastat/[®] Clesacostat[®]
Combination Therapy

Received FDA Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis

Candidate
Elranatamab

Announced interim efficacy results from ongoing Phase 2 study in people with advanced relapsed/refractory multiple myeloma

Proposed Acquisition
biohaven[®]
pharmaceuticals

Entered agreement to acquire calcitonin gene-related peptide (CGRP) migraine assets

Completed Acquisition
REVIRAL[®]

Completed acquisition of clinical stage biopharma focused on antiviral candidates for respiratory syncytial virus (RSV)

Vaccines Internal Medicine Inflammation/Immunology Oncology Rare Disease Hospital

1.2B

people in 45 lower-income countries

for whom we aim to provide all current and future patent-protected medicines & vaccines available in the U.S. / EU on a not-for-profit basis through Pfizer's health equity improvement initiative, 'An Accord for a Healthier World'

>3.6B

COVID-19 vaccine doses shipped to 180 countries to date

Advancing Robust Portfolio

Anticipated in the Next 18 Months⁷

Up to

15

Potential Approvals



Up to

14

Projected Pivotal Readouts



Up to

14

Potential Proof of Concept Readouts



What's Next

Reaffirm projected revenue CAGR of at least 6% and double-digit adjusted diluted EPS² growth through 2025⁸



Maintain

patient centricity



Scale

tech platforms



Invest

in areas we can win



Foster

a culture of innovation



Reduce

approval development cycle times

25 BY 2025

Ambition of up to 25 breakthrough launches in patients' hands by 2025